Volpara Health

What Volpara Health does

Volpara Health Technologies Limited is a New Zealand-originated medical AI software company founded in 2009 that builds tools for breast cancer detection and mammography quality management. Its product suite centers on automated breast density assessment (Volpara Scorecard), personalized breast cancer risk evaluation (Volpara Risk Pathways), mammography workflow analytics (Volpara Analytics), real-time image quality monitoring (Volpara Live), and patient-facing mammography reporting (Patient Hub). Core technology is built on deep learning models trained on diverse mammography and tomosynthesis image datasets, with computer vision, predictive analytics, and anomaly detection capabilities integrated into radiology workflows.

Volpara was acquired by South Korean medical AI company Lunit Inc. in May 2024 for $193 million and now operates as a wholly-owned subsidiary within Lunit's broader cancer screening and precision oncology portfolio. Post-acquisition, the Volpara suite is sold alongside Lunit's AI cancer detection products (Lunit INSIGHT MMG for 2D mammography, Lunit INSIGHT DBT for 3D tomosynthesis, Lunit INSIGHT CXR for chest X-ray) and its SCOPE biomarker/companion diagnostic line, forming an integrated breast cancer ecosystem deployed across more than 330 sites in 65+ countries and supporting over 1 million mammography examinations annually.

Revenue mechanics are enterprise B2B subscription licensing of AI radiology software to hospitals, radiology practices, and healthcare systems, sold through direct field sales and channel partnerships (including a 2025 ACR Learning Network Vendor Partner designation with the American College of Radiology). Customer segments are concentrated in healthcare providers and radiology practices, with secondary reach into academic medical centers. Pricing is quote-based and annual, typical of regulated medical AI deployments, with no public pricing disclosed. The company is now structurally part of Lunit Inc. (KRX: 328130), a publicly traded entity on the Korea Exchange.

Name

Volpara Health

Legal name

Volpara Health Technologies Limited

Website

https://volparahealth.com

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

5,001–10,000 employees

Short description

Volpara Health, founded in 2009 in New Zealand and acquired by Lunit Inc. for $193M in May 2024, develops AI-powered mammography quality management and breast cancer risk assessment software (Scorecard, Risk Pathways, Analytics, Live, Patient Hub) licensed via enterprise subscription to hospitals, radiology practices, and healthcare systems across 65+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Software Publishers (5132)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL)

akta.pro secondary industries

Teleradiology Platforms & Reading Workflow (HLACALAK), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Diagnostic & Triage Decision Support (HLACAGAA), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ)

Keywords

• AI mammography software
• Breast cancer screening
• Medical imaging AI
• Radiology software
• Cancer detection

Headquarters

HQ city

Wellington

HQ country

New Zealand

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical AI Software Licensing: Enterprise licensing of AI-powered mammography software to healthcare institutions. The software includes density assessment, risk assessment, quality management, and reporting solutions sold to hospitals and radiology practices.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Volpara Health provides AI-powered software solutions for breast cancer screening and mammography analysis. Its platform includes tools for mammography quality assurance, breast density assessment, cancer risk prediction, and AI-assisted cancer detection, primarily used by radiology clinics, hospitals, and breast imaging centers. Following acquisition by Lunit Inc. in May 2024, the offering has been integrated into Lunit's broader cancer screening ecosystem.

Product overview

Volpara Health, acquired by Lunit in May 2024 for $193 million, operates as part of Lunit's AI-powered cancer screening ecosystem. The product portfolio centers on breast cancer detection and includes the Volpara-branded mammography quality management suite (Volpara Scorecard, Volpara Risk Pathways, Volpara Analytics, Volpara Live) alongside Lunit's core AI radiology products (Lunit INSIGHT MMG for 2D mammography, Lunit INSIGHT DBT for 3D tomosynthesis, Patient Hub for mammography reporting). The Volpara products focus on mammography workflow optimization—automated density scoring, personalized risk assessment, quality analytics, and real-time monitoring—while Lunit INSIGHT products provide the underlying AI cancer detection capabilities. The combined ecosystem supports over 1 million mammography examinations annually across 200+ U.S. healthcare institutions.

Differentiator

Problem solved

Functional benefit

Brands

• Volpara Scorecard: Density assessment solution for mammography screening
• Volpara Risk Pathways
• Volpara Analytics
• Volpara Live

Products and services

• Volpara Scorecard
• Volpara Risk Pathways
• Volpara Analytics
• Volpara Live
• Patient Hub
• Lunit INSIGHT MMG
• Lunit INSIGHT DBT

Quantifiable outcome

• Over 1 million mammography examinations analyzed annually
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

One partnership is on record.

• American College of Radiology (ACR)coreStrategic or Co-development Partner · 16 October 2025Volpara Health was designated as ACR Learning Network Vendor Partner to improve mammography quality and breast cancer detection nationwide. The partnership focused on optimizing mammography positioning to meet ACR criteria, resulting in measurable improvements in image quality across healthcare providers through data-driven insights and technical improvement programs.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Hologic: Hologic is a direct competitor in 3D mammography (Selenia Dimensions) and bundles its Genius AI detection software with hardware, giving it distribution advantage in the same hospital radiology departments Volpara serves.
• GE HealthCare: GE HealthCare manufactures mammography systems (Senographe) and embeds AI breast imaging capabilities, competing with Volpara/Lunit as a broad incumbent that can bundle detection with hardware.
• Siemens Healthineers: Siemens Healthineers produces mammography modalities and AI-empowered breast imaging software (AI-Rad Companion), operating as a broad incumbent that overlaps with Volpara's mammography informatics portfolio.
• Fujifilm Healthcare: Fujifilm offers digital mammography systems and breast imaging IT, competing with Volpara as a broad incumbent with both hardware and radiology informatics offerings.
• Philips: Philips provides mammography systems (MicroDose) and broader radiology informatics, making it a broad incumbent whose enterprise imaging suite overlaps with Volpara's PACS-integrated workflow tools.
• Lunit Inc. Lunit is the parent company of Volpara following the May 2024 acquisition and directly operates INSIGHT MMG/DBT detection and the SCOPE precision-oncology suite, now integrating Volpara's quality and risk modules.

Direct peers

• iCAD, Inc. iCAD provides ProFound AI, a direct competitor to Lunit INSIGHT for breast cancer detection on mammography and DBT, sold to the same healthcare institution customer base.
• DeepHealth (RadNet subsidiary): DeepHealth (formerly iCAD) competes directly with Volpara/Lunit INSIGHT in AI-powered mammography detection and breast density assessment, serving similar hospital and outpatient imaging customers.
• ScreenPoint Medical: ScreenPoint Medical offers Transpara, a directly competing AI breast imaging detection and triage platform for 2D and 3D mammography, targeting the same radiology workflow as Lunit INSIGHT MMG/DBT and Volpara.
• Therapixel: Therapixel's MammoScreen is an AI mammography decision-support tool directly comparable to Lunit INSIGHT MMG and Volpara Scorecard, addressing the same radiologist reading workflow.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/volparahealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Volpara Health